Home / Going-concern warnings / Akari Therapeutics Plc
Filed 2025-04-15 路 Form 10-K 路 Accession 0000950170-25-054278 nano
Price before filing: $44.4 (2025-04-14 close, split/dividend-adjusted)
Market cap at flag: $755,328 (2025-04-15) 路 Latest: $14.7M (2026-10-16)
| Window | AKTX | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +18.9% | +9.5% | +9.4% | 2025-05-15 |
| 90 days | -0.9% | +16.2% | -17.1% | 2025-07-14 |
| 180 days | -15.1% | +23.7% | -38.8% | 2025-10-13 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations, defaults on debt obligations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: independent auditor report in Form 10-K (period 2024-12-31)
Why this score: in auditor's report
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.